IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies
“We are pleased to collaborate with Xcellon Biologics, a leading CDMO company,” said Tae Kyo Park, CEO of IntoCell. “We will endeavor to ensure the mutual success of both companies by combining respective areas of expertise. By integrating IntoCell’s proprietary OHPAS linker and payload platforms with Xcellon’s bioconjugation and manufacturing expertise, we aim to provide global innovators with the tools and support necessary to bring differentiated ADC therapies to patients faster.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.